Nycomed announced that the European Commission has granted marketing authorization for its Instanyl single-dose nasal spray for the management of breakthrough pain in cancer patients. The drug will be available in European countries in September 2011.
The launch of the single-dose nasal spray provides greater flexibility to the patient, can help manage dose titration and dose modification, and enable easier tracking of a patient’s use of rescue medication.
The single-dose nasal spray will be available in 50 µg, 100 µg, and 200 µg dose strengths.
Nycomed’s Instanyl fentanyl nasal spray was the first fast acting nasal opioid approved for the management of breakthrough pain in cancer patients.
Release Date: July 4, 2011
Filed Under: Drug Discovery